Gilead Sciences outlines its outlook for fiscal year 2026 in its latest report.
Show original
The company expects that, excluding adverse factors brought by policy changes, sales of its core business segment—HIV treatment drugs—will achieve steady growth, with fiscal year 2026 projected to increase by approximately 8% compared to fiscal year 2025. This growth expectation highlights the company’s continued market advantage and development potential in the antiviral field.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$68,704.39
-2.22%
Ethereum
ETH
$2,018.85
-4.20%
Tether USDt
USDT
$0.9994
-0.01%
XRP
XRP
$1.4
-2.87%
BNB
BNB
$619.74
-2.79%
USDC
USDC
$1.0000
+0.01%
Solana
SOL
$82.82
-4.79%
TRON
TRX
$0.2781
-0.21%
Dogecoin
DOGE
$0.09274
-3.74%
Bitcoin Cash
BCH
$524.5
-1.74%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now